{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:06:20Z","timestamp":1778961980657,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["RUG2011-5093"],"award-info":[{"award-number":["RUG2011-5093"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VIDI-91713334"],"award-info":[{"award-number":["VIDI-91713334"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["ERC-2011-293-445"],"award-info":[{"award-number":["ERC-2011-293-445"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["ERC-2011-293-445"],"award-info":[{"award-number":["ERC-2011-293-445"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["ERC-2011-293-445"],"award-info":[{"award-number":["ERC-2011-293-445"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"EC | European Research Council","doi-asserted-by":"publisher","award":["ERC-2011-293-445"],"award-info":[{"award-number":["ERC-2011-293-445"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41388-018-0522-7","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T11:45:31Z","timestamp":1539171931000},"page":"1477-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition"],"prefix":"10.1038","volume":"38","author":[{"given":"H. Rudolf","family":"de Boer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esm\u00e9\u00e9","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Everts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douwe F.","family":"Samplonius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry J. M.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"van Cooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Fusetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-315X","authenticated-orcid":false,"given":"Rudolf S. N.","family":"Fehrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth G. E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel A. T. M.","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14:57\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8274.CD-11-0051","volume":"1","author":"EGE Vries de","year":"2011","unstructured":"de Vries EGE, THO Munnink, van Vugt MATM, Nagengast WB. Toward molecular imaging-driven drug development in oncology. Cancer Discov. 2011;1:25\u20138.","journal-title":"Cancer Discov"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.7150\/thno.17934","volume":"7","author":"M Pool","year":"2017","unstructured":"Pool M, de Boer HR, Lub-de Hooge MN, van Vugt MATM, de Vries EGE. Harnessing integrative omics to facilitate molecular imaging of precision medicine of the human epidermal growth factor receptor family. Theranostics. 2017;7:2111\u201333.","journal-title":"Theranostics"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc.2016.56","volume":"16","author":"AJ Vargas","year":"2016","unstructured":"Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16:525\u201337.","journal-title":"Nat Rev Cancer"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djj129","volume":"98","author":"DP Petrylak","year":"2006","unstructured":"Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MHA, Lara PN, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516\u201321.","journal-title":"J Natl Cancer Inst"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","volume":"4","author":"T Forshew","year":"2012","unstructured":"Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68","journal-title":"Sci Transl Med"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1200\/JCO.2015.61.6425","volume":"33","author":"EGE Vries de","year":"2015","unstructured":"de Vries EGE, de Jong S, Gietema JA. Molecular imaging as a tool for drug development and trial design. J Clin Oncol. 2015;33:2585\u20137.","journal-title":"J Clin Oncol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282\u2013303.","journal-title":"Cancer Cell"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337\u201345.","journal-title":"N Engl J Med"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/1535-7163.MCT-11-0852","volume":"11","author":"K Kani","year":"2012","unstructured":"Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, et al. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012;11:1071\u201381.","journal-title":"Mol Cancer Ther"},{"key":"522_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-258","volume":"8","author":"KA Hoadley","year":"2007","unstructured":"Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007;8:258","journal-title":"BMC Genomics"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/1535-7163.MCT-06-0514","volume":"6","author":"F Yamasaki","year":"2007","unstructured":"Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007;6:2168\u201377.","journal-title":"Mol Cancer Ther"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1074\/jbc.275.10.6987","volume":"275","author":"D Busse","year":"2000","unstructured":"Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation ofp27(KIP1) independent of MAPK activity. J Biol Chem. 2000;275:6987\u201395.","journal-title":"J Biol Chem"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1074\/mcp.M200025-MCP200","volume":"1","author":"SE Ong","year":"2002","unstructured":"Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1:376\u201386.","journal-title":"Mol Cell Proteomics"},{"key":"522_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/ncb1501","volume":"8","author":"SC Wang","year":"2006","unstructured":"Wang S-C, Nakajima Y, Yu Y-L, Xia W, Chen C-T, Yang C-C, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006;8:1359\u201368.","journal-title":"Nat Cell Biol"},{"key":"522_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-11-r76","volume":"4","author":"SI Lee","year":"2003","unstructured":"Lee S-I, Batzoglou S. Application of independent component analysis to microarrays. Genome Biol. 2003;4:R76.","journal-title":"Genome Biol"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"DW Kufe","year":"2009","unstructured":"Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874\u201385.","journal-title":"Nat Rev Cancer"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acc.2015.05.001","volume":"71","author":"MJ Duffy","year":"2015","unstructured":"Duffy MJ, Walsh S, McDermott EW, Crown J. Biomarkers in breast cancer: where are we and where are we going? Adv Clin Chem. 2015;71:1\u201323.","journal-title":"Adv Clin Chem"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","volume":"17","author":"AB Turke","year":"2010","unstructured":"Turke AB, Zejnullahu K, Wu Y-L, Song Y, Dias-Santagata D, Lifshits E et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77\u201388.","journal-title":"Cancer Cell"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00259-017-3672-x","volume":"44","author":"M Pool","year":"2017","unstructured":"Pool M, Terwisscha van Scheltinga AGT, Kol A, Giesen D, de Vries EGE, Lub-de Hooge MN et al. 89Zr-Onartuzumab PET imaging of c-MET receptor dynamics. Eur J Nucl Med Mol Imaging. 2017;44:1328\u201336.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733\u201343.","journal-title":"N Engl J Med"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T. et al. LUX-LUNG 3 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:1\u201311.","journal-title":"J Clin Oncol"},{"key":"522_CR25","doi-asserted-by":"publisher","first-page":"11594","DOI":"10.1158\/0008-5472.CAN-06-4138","volume":"66","author":"DE White","year":"2006","unstructured":"White DE, Negorev D, Peng H, Ivanov AV, Maul GG, Rauscher FJ. et al. KAP1, a novel substrate for PIKK family members, colocalizes with numerous damage response factors at DNA lesions. Cancer Res. 2006;66:11594\u20139.","journal-title":"Cancer Res"},{"key":"522_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1535-6108(04)00020-0","volume":"5","author":"J Ren","year":"2004","unstructured":"Ren J, Agata N, Chen D, Li Y, Yu W, Huang L. et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5:163\u201375.","journal-title":"Cancer Cell"},{"key":"522_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154:442\u201351.","journal-title":"Cell"},{"key":"522_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1242\/dev.103341","volume":"141","author":"NA Kearns","year":"2013","unstructured":"Kearns NA, Genga RMJ, Enuameh MS, Garber M, Wolfe SA, Maehr R et al. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development. 2013;141:219\u201323.","journal-title":"Development"},{"key":"522_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159:647\u201361.","journal-title":"Cell"},{"key":"522_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437\u201341.","journal-title":"Nature"},{"key":"522_CR31","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.1018001108","volume":"109","author":"A Chakrabarty","year":"2012","unstructured":"Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109:2718\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"522_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58\u201371.","journal-title":"Cancer Cell"},{"key":"522_CR33","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Olivares MJ, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011;108:5021\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"522_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science"},{"key":"522_CR35","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1074\/jbc.M009449200","volume":"276","author":"IC Gaemers","year":"2001","unstructured":"Gaemers IC, Vos HL, Volders HH, Van der Valk SW, Hilkens J. A STAT-responsive element in the promoter of the episialin\/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem. 2001;276:6191\u20139.","journal-title":"J Biol Chem"},{"key":"522_CR36","doi-asserted-by":"publisher","first-page":"ra9","DOI":"10.1126\/scisignal.2001426","volume":"4","author":"R Ahmad","year":"2011","unstructured":"Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B. et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011;4:ra9","journal-title":"Sci Signal"},{"key":"522_CR37","doi-asserted-by":"publisher","first-page":"18140","DOI":"10.1074\/jbc.271.30.18140","volume":"271","author":"A Kovarik","year":"1996","unstructured":"Kovarik A, Lu PJ, Peat N, Morris J, Taylor-Papadimitriou J. Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter. J Biol Chem. 1996;271:18140\u20137.","journal-title":"J Biol Chem"},{"key":"522_CR38","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.cellsig.2010.06.014","volume":"22","author":"A Stars\u00edchov\u00e1","year":"2010","unstructured":"Stars\u00edchov\u00e1 A, Lincov\u00e1 E, Pernicov\u00e1 Z, Kozub\u00edk A, Soucek K. TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell Signal. 2010;22:1734\u201344.","journal-title":"Cell Signal"},{"key":"522_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7150\/jca.2.324","volume":"2","author":"NT Ueno","year":"2011","unstructured":"Ueno NT, Zhang D. Targeting EGFR in triple negative breast cancer. J Cancer. 2011;2:324\u20138.","journal-title":"J Cancer"},{"key":"522_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J, et al. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207\u201321.","journal-title":"Cancer Cell"},{"key":"522_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature19949","volume":"537","author":"R Aebersold","year":"2016","unstructured":"Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537:347\u201355.","journal-title":"Nature"},{"key":"522_CR42","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.celrep.2017.10.015","volume":"21","author":"P Savage","year":"2017","unstructured":"Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, et al. A targetable EGFR-dependent tumor-initiating program in breast cancer. Cell Rep. 2017;21:1140\u20139.","journal-title":"Cell Rep"},{"key":"522_CR43","doi-asserted-by":"publisher","first-page":"68111","DOI":"10.18632\/oncotarget.11827","volume":"7","author":"M Pool","year":"2016","unstructured":"Pool M, Kol A, Lub-de Hooge MN, Gerdes CA, de Jong S, de Vries EGE, et al. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. Oncotarget. 2016;7:68111\u201321.","journal-title":"Oncotarget"},{"key":"522_CR44","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1002\/ijc.23411","volume":"122","author":"N Ishikawa","year":"2008","unstructured":"Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122:2612\u201320.","journal-title":"Int J Cancer"},{"key":"522_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.lungcan.2007.07.018","volume":"59","author":"Y Fujiwara","year":"2008","unstructured":"Fujiwara Y, Kiura K, Toyooka S, Hotta K, Tabata M, Takigawa N, et al. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer. 2008;59:81\u20137.","journal-title":"Lung Cancer"},{"key":"522_CR46","first-page":"307","volume":"22","author":"A Bearz","year":"2008","unstructured":"Bearz A, Talamini R, Vaccher E, Spina M, Simonelli C, Steffan A, et al. MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients. Int J Biol Markers. 2008;22:307\u201311.","journal-title":"Int J Biol Markers"},{"key":"522_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/A:1017903724176","volume":"68","author":"R D\u2019Alessandro","year":"2001","unstructured":"D\u2019Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat. 2001;68:9\u201319.","journal-title":"Breast Cancer Res Treat"},{"key":"522_CR48","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.1505283112","volume":"112","author":"AM Heijink","year":"2015","unstructured":"Heijink AM, Blomen VA, Bisteau X, Degener F, Matsushita FY, Kaldis P. et al. A haploid genetic screen identifies the G 1\/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Proc Natl Acad Sci USA. 2015;112:15160\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"522_CR49","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367\u201372.","journal-title":"Nat Biotechnol"},{"key":"522_CR50","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1021\/pr101065j","volume":"10","author":"J Cox","year":"2011","unstructured":"Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10:1794\u2013805.","journal-title":"J Proteome Res"},{"key":"522_CR51","doi-asserted-by":"publisher","first-page":"D1063","DOI":"10.1093\/nar\/gks1262","volume":"41","author":"JA Vizca\u00edno","year":"2013","unstructured":"Vizca\u00edno JA, C\u00f4t\u00e9 RG, Csordas A, Dianes JA, Fabregat A, Foster JM. et al. The proteomics identifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013;41:D1063\u20139.","journal-title":"Nucleic Acids Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0522-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0522-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:06Z","timestamp":1684617246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0522-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0522-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"23 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}